Ursodeoxycholic acid (UDCA) is used for various therapeutic purposes. It became the treatment of choice in cholestatic syndromes by 1987 when Poupon et al. published the results of the first pilot study of UDCA treatment in patients with primary biliary cirrhosis (PBC)1. The Poupon initial study...
- 1995 - A1191 - www.sciencedirect.comdoi:10.1016/0016-5085(95)29067-2NoneELSEVIERGastroenterology
The effects of four different doses of ursodeoxycholic acid (250, 500, 750, and 1000 mg daily) on biliary lipids were studied in 24 patients with radiolucent gallbladder stones. There was a significant increase in the proportion of ursodeoxycholic acid in bile after all doses, being greatest ...
Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Background: Ursodeoxycholic acid (UDCA) is beneficial in cholestasis related to cystic fibrosis (CF). High-dose treatment has been recommended to...
Secondary bile acids (SBAs) including lithocholic acid (LCA), ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) are derived from PBAs by microbial flora in the large intestine16. PBAs and SBAs can be transformed into conjugated bile acids (CBAs), including t-CBAs and glycine-conjugated ...
Cell death and organ failure are the most commonly observed results of ischemia [1]. Interrupted blood flow and decreased transport of oxygen amount activate the anaerobic metabolism which leads to deposition of lactic acid and toxic metabolites in tissues, thus creating cellular injury [2]. ...
Carrion A, Borowitz DS, Freedman SD et al (2018) Reduction of recurrence risk of pancreatitis in cystic fibrosis with Ivacaftor: case series. J Pediatr Gastroenterol Nutr 66:451–454 PubMed Google Scholar Cheng K, Ashby D, Smyth RL (2017) Ursodeoxycholic acid for cystic fibrosis-related live...
Pruritus in hepatic cholestasis has been suggested to be secondary to a high concentration of serum bile acids. Rifampicin, which inhibits the uptake of bi... GV Gregorio,CS Ball,AP Mowat,... - 《Archives of Disease in Childhood》 被引量: 220发表: 1993年 Commentary: ursodeoxycholic acid as...
The following factors were not associated with hospitalization for more than 7 days: patient age, donor/recipient HLA-mismatch, donor sex, grade IIb acute GVHD at onset, and prophylactic use of ursodeoxycholic acid or BDP. Discussion This retrospective analysis of outcomes among 733 allograft ...
Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson's disease 2020, Journal of Controlled Release Citation Excerpt : Among other agents, natural compounds possessing these properties such as GER, an abundant component of ...